August 21, 2014 | Illumina today announced a series of collaborations with large pharmaceutical companies, to participate in patient stratification for the development of new cancer drugs by offering a multi-gene panel that covers key cancer mutations. The panel will be built for the FDA-approved MiSeqDx sequencer, making it easier to incorporate into both clinical trials and, eventually, clinical practice. Illumina's press release notes that "125 known cancer driver genes have been discovered," though it stops short of stating that the company's new oncology panel will cover all of them.